Fig. 5: Macrophage depletion reduces MIC β1KO recurrent tumor growth.
From: Osteopontin is a therapeutic target that drives breast cancer recurrence
a Schematic representation of experimental design for intraperitoneal injection of PBS- or clodronate-liposomes to MIC β1KO mice. Created in BioRender. Muller, W. (2024) BioRender.com/r58v392. b Tumor volume measured from weekly palpations of MIC β1KO mice treated with PBS- or clodronate-liposomes. Two-tailed Students’ t test was performed at endpoint and n denotes number of tumors per treatment arm. c Fluorescent IHC for F4/80, CD206, PanCK, and DAPI on tumors of MIC β1KO mice treated with PBS- or clodronate-liposomes (n = 4 per group). d, e Quantification of total F4/80+ cells and F4/80+ CD206+ cells in tumors of MIC β1KO mice treated with PBS- or clodronate-liposomes (n = 4 per group). f Fluorescent IHC for Ki67, PanCK, and DAPI on tumors of MIC β1KO mice treated with PBS- or clodronate-liposomes (n = 4 per group). g, h Quantification of total Ki67+ cells and Ki67+ PanCK+ cells in tumors of MIC β1KO mice treated with PBS- or clodronate-liposomes (n = 4 per group). i Fluorescent IHC for F4/80, CD206, PanCK, and DAPI on early invasive carcinoma from MIC WT lesions (fast-growing, n = 10) or MIC β1KO lesions (dormant, n = 19). j, k Quantification of total F4/80+ cells and F4/80+ CD206+ cells in early invasive carcinoma from MIC WT lesions (fast-growing, n = 10) or MIC β1KO lesions (dormant, n = 19). Scale bars are as indicated on each image. Mean ± SEM for data calculated using two-tailed Student’s t test unless otherwise specified. Each data point is representative of one biological sample for (d), (e), (g), (h), (j), and (k). Source data are provided as a Source Data file.
